Stephen Tsang, MD, PhD, reviews promising optogenetic therapy results for retinitis pigmentosa and Stargardt disease, enhancing vision and mobility for patients.
A panelist discusses how strategic eye selection and proactive patient counseling optimize success and satisfaction with NT-501 implantation for bilateral MacTel type 2. A panelist discusses how ...
A panelist discusses how evolving imaging and the approval of NT-501 therapy are transforming macular telangiectasia type 2 from a diagnostic challenge into a treatable condition. A panelist discusses ...
A panelist discusses how careful timing, patient education, and bilateral treatment planning strengthen real-world NT-501 management for MacTel type 2. A panelist discusses how key takeaways from ...
Sharon Fekrat, MD, FACS, FASRS, shares insights on the retinal manifestations of antipsychotic medications.
A panelist discusses how individualized imaging-based decisions guide when to initiate NT-501 therapy in both early and advanced stages of MacTel type 2. A panelist discusses how selecting the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback